Skip to main content

Advertisement

Figure 5 | EJNMMI Research

Figure 5

From: Synthesis, characterization, and preclinical validation of a PET radiopharmaceutical for interrogating Aβ (β-amyloid) plaques in Alzheimer’s disease

Figure 5

Time-activity curves (TACs) showing kinetics of [18F]-7B obtained from ROI of transgenic and WT mice. The SUV data were additionally normalized to the average activity measured in those regions between 1 and 2 min after injection. The normalized SUV data indicate a higher retention of the tracer in cortex of transgenic mice compared with its WT counterpart following a clearance of the unbound tracer, a pharmacokinetic profile consistent with binding of the agent ([18F]-7B) with Aβ plaques in transgenic mice. TG, ; WT, wild type; SUV, Standard Uptake Value.

Back to article page